Category: CLE, Commercial & Consumer Law (CLE), Criminal Law (CLE), District of Columbia Affairs, Education Law (CLE), Elder Law (CLE), Employment and Labor Law (CLE), Family Law, Government Law (CLE), Health Law, Intellectual Property Law, Litigation, Tort Law (show less)
Other: Administrative Law and Practice, Consumer Law, Corporate Finance and Securities Law, Courts Lawyers and the Administration of Justice, Criminal Law and Practice, District of Columbia Law, Education Law, Elder Law, Employee Benefits Law, Employment and Labor, Family, Health, Intellectual Property, Litigation, Torts, Veterans
(show less)
|
This class is eligible for CLE Passport use. If you purchased a CLE Passport during the license renewal season, we sent you a unique code and instructions for using your passport. Enter your code at checkout to purchase this class at no additional cost.
Credits: 2.0 Credit Hours
Description: While the COVID pandemic has had a dramatic impact on the United States and elsewhere, other public health issues – including the opioid crisis – continue to dramatically affect our society. Attend this informative and topical class and learn more about the regulation of opioid drugs and the legal issues involved in combating this crisis in the United States. Our expert panel will discuss how the US Food and Drug Administration (FDA) regulates and approves opioid drugs, including drugs intended to counteract addiction. The panel will also discuss how the US Drug Enforcement Administration (DEA) schedules opioid drugs and develops annual quotas and prevents diversion, and how pain and substance abuse treatment doctors from the American Medical Association’s perspective view these important regulatory issues and interact with the regulators at the FDA and DEA. Specific topics include:
- FDA approval of drugs including opioids with abuse deterrent mechanisms
- Overview of FDA’s new initiatives to help curb the opioid drug crisis
- Use of medications to rehabilitate patients addicted to pain medications
- History of the opioid drug problem
- DEA’s regulatory role to prevent drug diversion and abuse
- Physicians’ interaction with FDA/DEA regulation of opioids
- Physician prescribing of opioids and Best Practices
- Roles addressing opioid epidemic.
While this class is intended for those who deal with the regulatory and public health aspects of the opioid crises, others may find the topic of interest.
Faculty:
Daniel Blaney-Koen, American Medical Association
Brian J. Malkin, McDermott Will & Emery LLP
Patrick Raulerson, US Food and Drug Administration
Justin G. Wood, US Drug Enforcement Administration
Cosponsors:
D.C. Bar Administrative Law & Agency Practice Community
Criminal Law and Individual Rights Community
Health Law Community